Innovative Technology enables the pharmaceutical industry to
transition to an orchestrated commercial model
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
IQVIA™
(NYSE:IQV) today announced that Adhera
Therapeutics Inc. (OTCQB:ATRX) has selected Orchestrated
Customer Engagement (OCE), IQVIA Technologies’ transformational
commercial platform, to build its commercial infrastructure and bring
the company’s specialty drug innovations to patients.
OCE accelerates a transformation in commercial engagement for life
sciences companies by connecting functions, data, insights, and
activities horizontally to break down silos and provide a holistic view
of the customer. This gives the company and its clients, a streamlined,
more valuable customer experience. Adhera Therapeutics will leverage the
OCE technology platform to deliver more intelligent and actionable
insight to its commercial teams.
“We have confidence that IQVIA’s OCE platform will support our mission
to develop and commercialize unique pharmaceutical therapies and
leverage technology to improve patient outcomes,” said Robert C.
Moscato, Jr., chief executive officer of Adhera Therapeutics. “We wanted
to provide our sales team and home office users with the leading
technology to support our current business needs but also have a
customer relationship management solution that will support our future
needs as we grow.”
Pharmaceutical companies are making IQVIA’s OCE the new commercial
standard because it is easy to use, enables connectivity across all
commercial functions, and surfaces actionable insights into marketing
and sales teams’ workflow. The platform will allow Adhera to start from
scratch as it builds and strengthens a true commercial infrastructure
over time.
“We are pleased that Adhera will be implementing our OCE technology
platform,” said Tal Rosenberg, senior vice president, Global Technology
Solutions at IQVIA. “IQVIA has a proven portfolio of innovative
technology solutions including CRM specifically designed for life
sciences. Adhera understands that the value of our new OCE platform is
its ability to capitalize on this deep industry knowledge. In short, OCE
helps companies improve their customer engagement model by creating a
better user experience, connecting all commercial team members, and
efficiently delivering tailored insight to each unique commercial team
member.”
About Adhera Therapeutics
Adhera Therapeutics, Inc. is a specialty pharmaceutical company
leveraging technology to commercialize unique therapies and improve
patient outcomes. The company is initially focused on commercializing
PRESTALIA® (perindopril arginine and amlodipine besylate) through
DyrctAxess, a patient-centric treatment approach. Our PRESTALIA product
is approved by the US FDA for the treatment of hypertension to lower
blood pressure. Adhera is dedicated to identifying additional assets to
expand our commercial presence. Additional information can be found at www.adheratherapeutics.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions and contract research services to the life sciences
industry. Formed through the merger of IMS Health and Quintiles, IQVIA
applies human data science — leveraging the analytic rigor and clarity
of data science to the ever-expanding scope of human science — to enable
companies to reimagine and develop new approaches to clinical
development and commercialization, speed innovation and accelerate
improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA
delivers unique and actionable insights at the intersection of
large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
the information that helps its customers drive human health outcomes
forward. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers, and other healthcare stakeholders tap into
a deeper understanding of diseases, human behaviors, and scientific
advances, in an effort to advance their path toward cures. To learn
more, visit www.iqvia.com.
Click
here to subscribe to Mobile Alerts for IQVIA.
IQVIAFIN
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181120005323/en/
Tor Constantino
IQVIA Media Relations
tor.constantino@iqvia.com
+1.484.567.6732
or
Andrew
Markwick
IQVIA Investor Relations
andrew.markwick@iqvia.com
+1.973.257.7144
Source: IQVIA